OncoImmune: OncoImmune Launches First-in-human Clinical Trial for ONC-392 - The anti-CTLA-4 Antibody that Preserves CTLA4 Recycling for Safer and More Effective Immunotherapy

(marketscreener.com) OncoImmune, Inc. announced today that it has dosed the first patient in the first-in-human clinical trial of ONC-392, its novel, next generation anti-CTLA-4 antibody, at the University of California Davis Comprehensive Cancer Center on September 16, 2020. This is a Phase 1A/1B clinical trial designed to assess the safety, pharmacokinetics, and...https://www.marketscreener.com/news/latest/OncoImmune-Launches-First-in-human-Clinical-Trial-for-ONC-392-ndash-The-anti-CTLA-4-Antibody-that--31347287/?utm_medium=RSS&utm_content=20200923